Technical Analysis for HGEN - Humanigen, Inc.

Grade Last Price % Change Price Change
D 19.28 2.94% 0.55
HGEN closed up 2.94 percent on Wednesday, February 24, 2021, on 52 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical HGEN trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Multiple of Ten Bearish Other 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 2.94%
MACD Bearish Signal Line Cross Bearish 2.94%
Slingshot Bullish Bullish Swing Setup 2.94%
Upper Bollinger Band Walk Strength 2.94%
Multiple of Ten Bearish Other 2.94%
Bearish Engulfing Bearish -10.41%
Older End-of-Day Signals for HGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
20 DMA Resistance about 2 hours ago
Up 5% about 5 hours ago
60 Minute Opening Range Breakout about 5 hours ago
Up 3% about 8 hours ago
Up 2% about 8 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Humanigen, Inc. Description

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.


Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine Immune System Infectious Diseases Immunotherapy Treatment Of Cancer Cancers Lymphoma Gene Therapy Dysfunction Infection Coronavirus Transplantation Hematopoietic Stem Cell Cytokine Cytokines Chimeric Antigen Receptor T Cell Sars Gilead Sciences Host Disease Platform Technologies Treatment Of Cancers Graft Versus Host Disease Eosinophil Coronavirus Infection Cytokine Release Syndrome Solid Cancers

Is HGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 33.95
52 Week Low 1.645
Average Volume 1,036,911
200-Day Moving Average 15.21
50-Day Moving Average 18.38
20-Day Moving Average 20.18
10-Day Moving Average 20.64
Average True Range 2.16
ADX 33.26
+DI 25.58
-DI 18.18
Chandelier Exit (Long, 3 ATRs ) 18.14
Chandelier Exit (Short, 3 ATRs ) 23.99
Upper Bollinger Band 22.88
Lower Bollinger Band 17.49
Percent B (%b) 0.33
BandWidth 26.74
MACD Line 0.68
MACD Signal Line 0.95
MACD Histogram -0.2688
Fundamentals Value
Market Cap 995.17 Million
Num Shares 51.6 Million
EPS -0.09
Price-to-Earnings (P/E) Ratio -209.57
Price-to-Sales 0.00
Price-to-Book 15.12
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.43
Resistance 3 (R3) 21.48 20.83 21.07
Resistance 2 (R2) 20.83 20.28 20.80 20.95
Resistance 1 (R1) 20.05 19.94 20.44 20.00 20.83
Pivot Point 19.40 19.40 19.59 19.37 19.40
Support 1 (S1) 18.62 18.85 19.01 18.57 17.73
Support 2 (S2) 17.97 18.51 17.94 17.61
Support 3 (S3) 17.19 17.97 17.49
Support 4 (S4) 17.14